ELISA, to detect/quantitate Factor XII and in coagulation assays. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.95 mg/mL
Buffer
PBS, pH 7.4, without preservative
Konservierungsmittel
Without preservative
Handhabung
Aliquot to Avoid multiple freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Upon receipt, store at -20 °C to -70 °C.
Target
F12
(Coagulation Factor XII (F12))
Hintergrund
Coagulation factor XII circulates in blood as a zymogen. This single chain zymogen is converted to a two chain serine protease with an heavy chain (alpha factor XIIa) and a light chain. The heavy chain contains two fibronectin type domains, two epidermal growth factor (EGF) like domains, a kringle domain and a proline rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta factor XIIa light chain and the alpha factor XIIa light chain becomes beta factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha factor XIIa and then to beta factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in Factor XII gene do not cause any clinical symptoms and the sole effect is that whole blood clotting time is prolonged.Synonyms: HAF, Hageman factor